Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.7%

34 terminated/withdrawn out of 216 trials

Success Rate

80.5%

-6.0% vs industry average

Late-Stage Pipeline

19%

40 trials in Phase 3/4

Results Transparency

42%

59 of 140 completed trials have results

Key Signals

22 recruiting59 with results27 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 1

118(59.3%)

Phase 2

37(18.6%)

Phase 3

32(16.1%)

Phase 4

8(4.0%)

N/A

4(2.0%)

199Total

Phase 1(118)

Phase 2(37)

Phase 3(32)

Phase 4(8)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (216)

Showing 20 of 216 trials

NCT07425574Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Role: lead

NCT05083481Phase 1Terminated

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Role: lead

NCT05365581Phase 1Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Role: lead

NCT07287995Phase 1Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Role: lead

NCT06779773Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Role: lead

NCT07566156Phase 3Recruiting

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Role: lead

NCT07140016Phase 1Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT07566052Phase 3Recruiting

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Role: lead

NCT06901531Phase 3Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Role: lead

NCT07475806Phase 2Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Role: lead

NCT06049797Completed

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Role: lead

NCT03816163Phase 2Active Not Recruiting

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Role: lead

NCT07488676Phase 1Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Role: lead

NCT07409272Phase 3Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Role: lead

NCT04223856Phase 3Active Not Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Role: lead

NCT06171178Phase 1Terminated

A Study of ASP1012 in Adults With Solid Tumors

Role: lead

NCT04184895Phase 1Active Not Recruiting

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Role: lead

NCT06862219Phase 4Recruiting

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer